EE200100660A - Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake - Google Patents

Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake

Info

Publication number
EE200100660A
EE200100660A EEP200100660A EEP200100660A EE200100660A EE 200100660 A EE200100660 A EE 200100660A EE P200100660 A EEP200100660 A EE P200100660A EE P200100660 A EEP200100660 A EE P200100660A EE 200100660 A EE200100660 A EE 200100660A
Authority
EE
Estonia
Prior art keywords
acid
microsphere
formulation
preparation
labile
Prior art date
Application number
EEP200100660A
Other languages
English (en)
Inventor
Dietrich Rango
Linder Rudolf
Original Assignee
Byk Gulden Lomberg Chemische Fabrik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik Gmbh filed Critical Byk Gulden Lomberg Chemische Fabrik Gmbh
Publication of EE200100660A publication Critical patent/EE200100660A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100660A 1999-06-07 2000-05-31 Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake EE200100660A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99110865 1999-06-07
PCT/EP2000/004958 WO2000074654A1 (en) 1999-06-07 2000-05-31 Novel preparation and administration form comprising an acid-labile active compound

Publications (1)

Publication Number Publication Date
EE200100660A true EE200100660A (et) 2003-04-15

Family

ID=8238296

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100660A EE200100660A (et) 1999-06-07 2000-05-31 Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake

Country Status (31)

Country Link
US (3) US7794752B1 (et)
EP (2) EP1187601B1 (et)
JP (1) JP4980527B2 (et)
KR (1) KR100833633B1 (et)
CN (1) CN1361683A (et)
AT (1) ATE300285T1 (et)
AU (1) AU775995B2 (et)
BG (1) BG106165A (et)
BR (1) BR0011347A (et)
CA (1) CA2376202C (et)
CZ (1) CZ20014405A3 (et)
DE (1) DE60021570T2 (et)
DK (1) DK1187601T3 (et)
EA (2) EA006899B1 (et)
EE (1) EE200100660A (et)
ES (1) ES2246238T3 (et)
HK (1) HK1046643A1 (et)
HR (1) HRP20020006A2 (et)
HU (1) HUP0201637A3 (et)
IL (2) IL146504A0 (et)
MX (1) MXPA01012659A (et)
NO (1) NO20015980L (et)
PL (1) PL352882A1 (et)
PT (1) PT1187601E (et)
SI (1) SI1187601T1 (et)
SK (1) SK285247B6 (et)
TR (1) TR200103527T2 (et)
UA (1) UA74339C2 (et)
WO (1) WO2000074654A1 (et)
YU (1) YU86001A (et)
ZA (1) ZA200110000B (et)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
WO2002045694A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
SI1341524T1 (sl) 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005074898A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
EP2046452A2 (en) * 2006-08-03 2009-04-15 Prosensa Technologies B.V. Antibiotic composition
CN103349659A (zh) * 2006-09-26 2013-10-16 塔罗制药北美有限公司 液体药物组合物以及应用
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR101094231B1 (ko) 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
CN103550214A (zh) * 2008-03-26 2014-02-05 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
AU2009288108B2 (en) 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
KR101107609B1 (ko) * 2009-09-21 2012-01-25 주식회사 한양비이에스티교육 태양에너지 발전 및 응용 교육을 위한 보트형 학습교재
EP2338477A1 (en) 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Suppository comprising pantoprazole
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012171540A1 (en) 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
AU2014350208B2 (en) * 2013-11-13 2017-09-07 Tillotts Pharma Ag Multi-particulate drug delivery system
CN107007561B (zh) * 2017-04-21 2019-12-03 湖南赛隆药业有限公司 一种左旋泮托拉唑钠缓释微球及其制备方法
CN107412171B (zh) * 2017-04-21 2020-04-17 湖南赛隆药业有限公司 注射用左旋泮托拉唑钠长效微球冻干制剂及其制备方法
EP3752236B1 (en) 2018-02-15 2023-12-27 Boston Scientific Scimed, Inc. Introducer with expandable capabilities
EP3927715A4 (en) 2019-02-21 2023-03-01 Chromadex, Inc. USE OF NICOTINAMIDE RIBOSIDE, NICOTINOIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS AND NICOTINYL RIBOSIDE COMPOUNDS IN FORMULATIONS

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE27C (de) * 1877-08-02 GRAHL und HÖHL zu Dresden Akkumulator zum Betriebe von Hutpressen
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
DE2725924C3 (de) * 1977-06-08 1980-11-06 Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau Verfahren zur Herstellung kugelförmiger Teilchen aus niedrigschmelzenden organischen Substanzen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
NO152588C (no) 1979-12-19 1985-10-23 Goudsche Machinefabriek Bv Kontinuerlig arbeidende krystallisator.
JPS58116471A (ja) 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd ４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
US4637966A (en) * 1983-10-21 1987-01-20 Gates Energy Products, Inc. Sealed lead-acid cell
US4876094A (en) * 1984-01-13 1989-10-24 Battelle Development Corporation Controlled release liquid dosage formulation
JPS60248618A (ja) * 1984-05-24 1985-12-09 Nippon Zoki Pharmaceut Co Ltd ジペプチドを含有する潰瘍治療剤
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
ES2032394T3 (es) 1986-02-20 1993-02-16 Hoechst Aktiengesellschaft Procedimiento para preparar derivados de tienoimidazol sustituidos.
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
CA1256109A (en) 1986-09-10 1989-06-20 Franz Rovenszky Process for the preparation of derivatives of 4, 5-dihydrooxazoles
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JP2681373B2 (ja) 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
EP0434999B1 (en) 1989-11-29 1994-08-17 Toa Eiyo Ltd. Cycloheptenopyridine derivatives, process for preparation thereof and antiulcer agents containing the same
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
DE4018642C2 (de) 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
DE4022648C2 (de) 1990-07-17 1994-01-27 Nukem Gmbh Verfahren und Vorrichtung zur Herstellung von kugelförmigen Teilchen aus flüssiger Phase
TW209174B (et) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
KR0141909B1 (ko) * 1991-11-08 1998-06-15 보조 다꾸로 액정 표시 디바이스 제조 방법
JP2973751B2 (ja) * 1991-12-04 1999-11-08 大正製薬株式会社 矯味経口組成物の製造方法
TW272942B (et) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
FR2707184B1 (fr) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
NL9400618A (nl) 1994-04-18 1995-12-01 Goudsche Machinefabriek Bv Inrichting voor het koelen en verwerken van een gesmolten produkt tot een granulaatprodukt.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DK1078628T3 (da) 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2754177B1 (fr) 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
NZ335737A (en) * 1996-11-12 2000-09-29 Pharmacia & Upjohn Ab Compact member comprising a plurality of porous cellulose matrices (PCMs)
GB9710800D0 (en) 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
ID20812A (id) * 1997-07-09 1999-03-11 Takeda Chemical Industries Ltd Senyawa polyol, produk dan penggunaannya
ES2234139T3 (es) * 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE500815T1 (de) 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
NL1007904C2 (nl) 1997-12-24 1999-06-25 Goudsche Machinefabriek Bv Werkwijze en inrichting voor het vormen van granulaat uit een smelt van chemische producten.
CN1293576A (zh) * 1998-03-20 2001-05-02 兴和株式会社 胃和/或十二指肠粘附性药物组合物
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
JP4370429B2 (ja) 1998-09-10 2009-11-25 東和薬品株式会社 徐放性マイクロスフエアの製造法
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz

Also Published As

Publication number Publication date
US7790198B2 (en) 2010-09-07
EA005803B1 (ru) 2005-06-30
CZ20014405A3 (cs) 2002-04-17
YU86001A (sh) 2004-07-15
MXPA01012659A (es) 2003-09-04
CN1361683A (zh) 2002-07-31
US20060127477A1 (en) 2006-06-15
UA74339C2 (uk) 2005-12-15
AU5074100A (en) 2000-12-28
KR100833633B1 (ko) 2008-05-30
HK1046643A1 (zh) 2003-01-24
SK285247B6 (sk) 2006-09-07
DE60021570T2 (de) 2006-05-24
WO2000074654A1 (en) 2000-12-14
JP4980527B2 (ja) 2012-07-18
HUP0201637A2 (hu) 2002-11-28
CA2376202C (en) 2008-11-18
BG106165A (bg) 2002-09-30
SI1187601T1 (sl) 2005-12-31
AU775995B2 (en) 2004-08-19
DE60021570D1 (de) 2005-09-01
EP1187601A1 (en) 2002-03-20
US7785630B2 (en) 2010-08-31
IL146504A0 (en) 2002-07-25
TR200103527T2 (tr) 2002-04-22
EA200101266A1 (ru) 2002-06-27
ES2246238T3 (es) 2006-02-16
US20080069882A1 (en) 2008-03-20
ATE300285T1 (de) 2005-08-15
BR0011347A (pt) 2002-03-19
DK1187601T3 (da) 2005-11-21
EP1616562A1 (en) 2006-01-18
PT1187601E (pt) 2005-11-30
NO20015980L (no) 2002-01-23
JP2003501377A (ja) 2003-01-14
EA200401241A1 (ru) 2005-02-24
NO20015980D0 (no) 2001-12-06
SK18022001A3 (sk) 2002-04-04
PL352882A1 (en) 2003-09-22
CA2376202A1 (en) 2000-12-14
US7794752B1 (en) 2010-09-14
IL146504A (en) 2007-02-11
ZA200110000B (en) 2002-12-24
EA006899B1 (ru) 2006-04-28
KR20020011997A (ko) 2002-02-09
HUP0201637A3 (en) 2004-05-28
HRP20020006A2 (en) 2003-04-30
EP1187601B1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
NO20015980D0 (no) Ny preparat- og administrasjonsform omfattende en syrelabil aktiv forbindelse
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
FI905781L (fi) Menetelmä farmaseuttisten koostumusten valmistamiseksi, jotka sisältävät sokerialkoholia ja homogeenisesti dispergoituna hiukkasmaista aktiivista yhdistettä
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
BR8801242A (pt) Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao
PT100234A (pt) Novos esteres de alcoois aminados biciclicos e triciclicos, processo para a sua preparacao
ATE427925T1 (de) Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
IT1230742B (it) Composizione per aerosol comprendente nitroglicerina come ingrediente attivo.
PT95312A (pt) Processo para a preparacao de novos tienilcarboxilatos de aminoalcoois e dos seus produtos de quaternizacao, e de composicoes farmaceuticas que os contem
NO981747L (no) Mikroinnkapslede insekticidpreparater og en fremgangsmÕte for fremstilling av disse
DE59711477D1 (de) Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
ATE332894T1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
KR970703131A (ko) 소수성 활성물질과 발포제를 포함하는 제약학적 조성물과 이의 준비공정(pharmaceutical preparation with a hydrophobic active substance and an effer vescent system, and process for preparing said preparation)
BR9706214A (pt) Composições farmacêuticas de liberação controlada para administração oral contendo nifedipina como substância ativa e processo para a preparação de composiç es farmacêuticas para a administração oral contendo nifedipina como substância ativa
AR026451A1 (es) Compuestos heterociclicos sililados
GEP20053581B (en) Pharmaceutical Composition and Method for Preparation Thereof
CA2239313A1 (en) Solid compound, its preparation and use in medicine
PT95810A (pt) Processo para a preparacao de composicoes farmaceuticas injectaveis contendo um alcaloide de bis-indol como ingrediente activo
NO950950L (no) Farmasöytisk preparat
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
DE3850044D1 (de) Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten.
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
ECSP941154A (es) Procedimiento para preparar una composicion farmaceutica a base de ciclosporina

Legal Events

Date Code Title Description
HC1A Change of owner name